#128 Developing a unique patented method of producing pharmaceutical-grade, rare cannabinoids with Dennis O’Neill

13:52
 
シェア
 

Manage episode 302435976 series 2817023
著作 CBD School の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。

Dennis O’Neill is the President of BioMediCan, a biotech startup company that has developed a unique patented method of producing pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids, including CBG, CBGA, THCV, THCVA, CBN, CBNA and high-value compounds using a proprietary organic biosynthesis platform at 70-90% lower cost than conventional methods.
The Cannabinoids 'CBD" Market is experiencing astronomical grow rates expecting the market to be $146 billion by 2026. There are over 200 known Cannabinoids many that are significantly more effective for treating multiple medical conditions than CBD's. The problem is it takes a significant amount of time to produce, is very expensive and there is a limited amounts that can be produced. BioMediCan has developed a bio-synthesized process where they can produce significant quantities that are free from Pesticide's/Contaminants"safer" at a fraction of the cost. We believe that this creates a significant opportunity to develop and sell mass quantities of these rare cannabinoids that are free of THC to the Global Market. BioMedican has a world-class scientific management team and 4 patents pending

Highlights

  • How BioMediCan was founded and it’s unique value proposition
  • Producing high-quality, low-cost non-THC products that circumvent FDA regulations
  • Producing rare cannabinoids
  • Health benefits of CBG, THCV, CBN

Links of Interest

128 つのエピソード